Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Authors: Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C van Heemst, Magdolen Youssef-El Soud, Harry J M Groen, Agnes J Staal-van den Brekel, Wieneke A Buikhuisen, Gerben P Bootsma, Floris Dammeijer, Harm van Tinteren, Ferry Lalezari, Joachim G Aerts, Jacobus A Burgers

Published: 2021-01-27

DOI: 10.1016/s2213-2600(20)30362-3

Source: Full article


Abstract

No abstract found.